← Browse by Condition
Medical Condition

recurrent chronic lymphocytic leukemia

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1
NCT04169737 Phase 2
Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Enrollment
168 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT07061951 Phase 2
Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Enrollment
20 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07166419 Phase 1
Recruiting

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Enrollment
24 pts
Location
United States
Sponsor
Ohio State University Comprehe...
View Trial →